Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/bergenbio-reports-third-quarter-2023-financial-results-301987030.html
https://www.prnewswire.com/news-releases/bergenbio-announces-data-from-biomarker-analyses-in-2l-nsclc-301978174.html
https://www.prnewswire.com/news-releases/bergenbio-announces-poster-presentation-at-upcoming-sitc-meeting-301972852.html
https://www.prnewswire.com/news-releases/additional-data-on-bergenbios-selective-axl-inhibitor-bemcentinib-to-be-presented-at-the-2023-esmo-meeting-301957048.html
https://www.prnewswire.com/news-releases/bergenbio-asa-approval-and-publication-of-prospectus-for-the-preferential-rights-issue-301835679.html
https://www.prnewswire.com/news-releases/bergenbio-presents-data-on-stk11-loss-of-function-and-axl-activation-at-aacr-301799845.html
https://www.prnewswire.com/news-releases/bergenbio-announces-first-patient-dosed-in-phase-1b2a-trial-evaluating-bemcentinib-in-1st-line-non-small-cell-lung-cancer-with-stk11-mutations-301767796.html
https://www.prnewswire.com/news-releases/bergenbio-reports-fourth-quarter-2022-financial-results-and-provides-business-update-301748474.html
https://www.prnewswire.com/news-releases/bergenbio-announces-positive-data-from-phase-2-trial-of-bemcentinib-in-combination-with-pembrolizumab-in-2l-nsclc-patients-301747787.html
https://www.prnewswire.com/news-releases/bergenbio-announces-the-establishment-of-oncology-scientific-advisory-board-301737026.html